The Antidote: PD reversed (from 51:30) - Cure Parkinson's
The Antidote: PD reversed (from 51:30)
No nicotine does not reverse Parkinson's, nor brain tumors.
link.springer.com/article/1...
"Several human studies have assessed the effects of nicotine gum or patch in PD, most of which have not yielded positive results (Vieregge et al. 2001; Lemay et al. 2004; see also Tizabi and Getachew 2017). "
this guy also supposedly says that there is snake venom in covid vaccine and that is our main problem - call me a major skeptic
INACCURATE
Claim:
COVID-19 is caused by snake venom, not a virus; snake venom is in the COVID-19 vaccines
so what about all the folks who got covid who were never vaccinated?
Lords of Mercy
We have never had covid and hope to keep it that way but probably fairly OCD in preventive measures on that- I surely do not want my husband to have to deal with that
is there a physiological argument and is there evidence that nicotine could reverse Parkinsons?
Openevidence.com says:
There is a physiological basis and emerging evidence suggesting that nicotine may have neuroprotective effects in Parkinson's disease (PD). Epidemiological studies have shown an inverse relationship between tobacco use and the incidence of PD, which has led to investigations into nicotine, a major component of tobacco, as a potential therapeutic agent.[1-2]
Nicotine appears to exert its effects primarily through the activation of nicotinic acetylcholine receptors (nAChRs). Various studies have demonstrated that nicotine can protect dopaminergic neurons in animal models of PD by interacting with these receptors. Specifically, nicotine has been shown to reduce neuroinflammation, oxidative stress, and neuronal apoptosis, which are key pathological features in PD.[1-6] Additionally, nicotine has been found to induce neuroplastic changes in the substantia nigra, promoting the expression of dopaminergic markers in non-dopaminergic neurons, which could compensate for the loss of dopaminergic neurons typical in PD.[4]
Moreover, molecular pathways such as the inhibition of PARP-1 and caspase-3 cleavage, suppression of SIRT6, and modulation of JNK and ERK signaling pathways have been implicated in the neuroprotective effects of nicotine.[3][5-6] These pathways are crucial in cell survival and death processes, suggesting that nicotine may help mitigate the progressive neuronal loss observed in PD.
While these findings are promising, it is important to note that they are primarily derived from preclinical studies. Further research, including clinical trials, is necessary to fully understand the potential therapeutic role of nicotine in PD management and to establish appropriate dosages and administration routes.
1.
Nicotine as a Potential Neuroprotective Agent for Parkinson's Disease.
Quik M, Perez XA, Bordia T.
Movement Disorders : Official Journal of the Movement Disorder Society. 2012;27(8):947-57. doi:10.1002/mds.25028.
2.
Beneficial Effects of Nicotine, Cotinine and Its Metabolites as Potential Agents for Parkinson's Disease.
Barreto GE, Iarkov A, Moran VE.
Frontiers in Aging Neuroscience. 2014;6:340. doi:10.3389/fnagi.2014.00340. Copyright License: CC BY
3.
The Neuroprotective Effect of Nicotine in Parkinson's Disease Models Is Associated With Inhibiting PARP-1 and Caspase-3 Cleavage.
Lu JYD, Su P, Barber JEM, et al.
PeerJ. 2017;5:e3933. doi:10.7717/peerj.3933. Copyright License: CC BY
4.
Nicotine-Mediated Recruitment of GABAergic Neurons to a Dopaminergic Phenotype Attenuates Motor Deficits in an Alpha-Synuclein Parkinson's Model.
Lai JI, Porcu A, Romoli B, et al.
International Journal of Molecular Sciences. 2023;24(4):4204. doi:10.3390/ijms24044204. Copyright License: CC BY
5.
Nicotine Promotes Neuron Survival and Partially Protects From Parkinson's Disease by Suppressing SIRT6.
Nicholatos JW, Francisco AB, Bender CA, et al.
Acta Neuropathologica Communications. 2018;6(1):120. doi:10.1186/s40478-018-0625-y. Copyright License: CC BY
6.
Nicotine Alleviates MPTP-induced Nigrostriatal Damage Through Modulation of JNK and ERK Signaling Pathways in the Mice Model of Parkinson's Disease.
Ruan S, Xie J, Wang L, et al.
Frontiers in Pharmacology. 2023;14:1088957. doi:10.3389/fphar.2023.1088957. Copyright License: CC BY
But remember it's nicotine, so it becomes a risk tradeoff if you want to play with it
What are the lowest risk ways to consume nicotine long term and what risks remain?
Openevidence.com
The lowest risk ways to consume nicotine long-term are through nicotine replacement therapy (NRT) products and potentially through electronic nicotine delivery systems (ENDS), such as e-cigarettes. NRT products, including patches, gums, and lozenges, are widely recognized for their role in smoking cessation and are considered safer than smoking combustible cigarettes. They provide controlled doses of nicotine to alleviate withdrawal symptoms while avoiding the carcinogens and toxins present in cigarette smoke.[1-2]
E-cigarettes are another alternative that may pose lower risks compared to traditional cigarettes. They do not burn tobacco, thus reducing the user's exposure to combustion-related carcinogens and toxins. Studies have shown that e-cigarette users have significantly lower levels of tobacco-specific nitrosamines and volatile organic compounds compared to those who smoke combustible cigarettes.[1][3] However, e-cigarettes are not risk-free. They can expose users to other potentially harmful substances and the long-term health effects are not fully understood.[3-4]
Despite the reduced risk profiles of NRT and ENDS compared to combustible cigarettes, risks remain. NRT products can still pose cardiovascular risks, especially in individuals with pre-existing heart conditions, and should be used cautiously.[5] E-cigarettes, while reducing some risks, still expose users to nicotine, which is addictive and can have adverse effects on cardiovascular and respiratory health.[3-4]
In conclusion, while NRT and ENDS offer lower-risk alternatives for long-term nicotine consumption compared to combustible cigarettes, they are not completely devoid of risks, and their use should be carefully considered and monitored.
1.
Nicotine, Carcinogen, and Toxin Exposure in Long-Term E-Cigarette and Nicotine Replacement Therapy Users: A Cross-Sectional Study.
Shahab L, Goniewicz ML, Blount BC, et al.
Annals of Internal Medicine. 2017;166(6):390-400. doi:10.7326/M16-1107.
Leading Journal
2.
Pharmacotherapy for Nicotine Dependence.
Henningfield JE, Fant RV, Buchhalter AR, Stitzer ML.
CA: A Cancer Journal for Clinicians. 2005 Sep-Oct;55(5):281-99; quiz 322-3, 325. doi:10.3322/canjclin.55.5.281.
Leading Journal
3.
Key Issues Surrounding the Health Impacts of Electronic Nicotine Delivery Systems (ENDS) and Other Sources of Nicotine.
Drope J, Cahn Z, Kennedy R, et al.
CA: A Cancer Journal for Clinicians. 2017;67(6):449-471. doi:10.3322/caac.21413.
Leading Journal
4.
E-Cigarettes: Use, Effects on Smoking, Risks, and Policy Implications.
Glantz SA, Bareham DW.
Annual Review of Public Health. 2018;39:215-235. doi:10.1146/annurev-publhealth-040617-013757. Copyright License: CC BY
Leading Journal
5.
Nicotrol. Label via DailyMed.
Food and Drug Administration (DailyMed)
Updated date: 2022-05-31
Slowing the Progression of PD (adapted from a book)
Would hyperbaric oxygen therapy (HBOT) along with Tasigna therapy be worth a look?
PD and the Children
PD and the bladder
nicotine from e-cigs for PD
